SavedAdd your journal

Journals / BEYOGLU EYE JOURNAL / 2017 / Cilt: 2 - Sayı: 1

Imiquimod 5% Cream for Treatment of Actinic Keratosis of the Eyelid

Gamze OZTURK KARABULUT
Korhan FAZIL
CAN ÖZTÜRKER
Berna BAŞARIR
Mühittin TAŞKAPILI
Pelin KAYNAK
Pages
29–32
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Although surgery is first-line treatment for these lesions, in case of refusal to undergo surgery, when lesion is superficial and diffuse and in region where reconstruction would be difficult, treatment with IMQ may be preferred.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:A 61-year-old male presented with 20 x 15 mm diffuse, hyperpigmented lesion that covered the right upper eyelid and which had been present for 2 years.
📊
Key Findings & Data:Since the patient refused surgery and reconstruction, he was treated with imiquimod (IMQ) 5% cream once a day, 5 times per week for 6 weeks.
💡
Conclusion & Impact:Although surgery is first-line treatment for these lesions, in case of refusal to undergo surgery, when lesion is superficial and diffuse and in region where reconstruction would be difficult, treatment with IMQ may be preferred.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

A 61-year-old male presented with 20 x 15 mm diffuse, hyperpigmented lesion that covered the right upper eyelid and which had been present for 2 years. Lesion was diagnosed as actinic keratosis (AK). Since the patient refused surgery and reconstruction, he was treated with imiquimod (IMQ) 5% cream once a day, 5 times per week for 6 weeks. Lesion gradually reduced in size and no clinically evident residual keratosis was observed after treatment. No post-therapy excision was performed to assess histological clearance of AK for cosmetic reasons. Although surgery is first-line treatment for these lesions, in case of refusal to undergo surgery, when lesion is superficial and diffuse and in region where reconstruction would be difficult, treatment with IMQ may be preferred.

🔖

Cite This Article

KARABULUT, G. O., FAZIL, K., ÖZTÜRKER, C., BAŞARIR, B., TAŞKAPILI, M., KAYNAK, P. (2017). Imiquimod 5% Cream for Treatment of Actinic Keratosis of the Eyelid. BEYOGLU EYE JOURNAL, Cilt: 2 - Sayı: 1, 29–32. https://ajindex.com/articles/147027

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (14)

  1. Hadley G, Derry S, Moore RA. Imiquimod for actinic keratosis: systematic review and meta-analysis. J Invest Dermatol 2006;126:1251-5
  2. Martin G. The impact of the current United States guidelines on the management of actinic keratosis: is it time for an update? J Clin Aesthet Dermatol 2010;3:20-5
  3. Kopera D, Kerl H. Visualization and treatment of subclinical actinic keratoses with topical imiquimod 5% cream: an observational study. Biomed Res Int 2014;2014:135916
  4. Lagler CN, Freitag SK. Management of periocular actinic keratosis: a review of practice patterns among ophthalmic plastic surgeons. Ophthal Plast Reconstr Surg 2012;28:277-81
  5. Leppälä J, Kaarniranta K, Uusitalo H, Kontkanen M. Imiquimod in the treatment of eyelid basal cell carcinoma. Acta Ophthalmol Scand 2007;85:566-8
  6. Blasi MA, Giammaria D, Balestrazzi E. Immunotherapy with imiquimod 5% cream for eyelid nodular basal cell carcinoma. Am J Ophthalmol 2005;140:1136-9
  7. Choontanom R, Thanos S, Busse H, Stupp T. Treatment of basal cell carcinoma of the eyelids with 5% topical imiquimod: a 3-year follow-up study. Graefes Arch Clin Exp Ophthalmol 2007;245:1217-20
  8. Carneiro RC, de Macedo EM, Matayoshi S. Imiquimod 5% cream for the treatment of periocular Basal cell carcinoma. Ophthal Plast Reconstr Surg 2010;26:100-2
  9. Tandon Y, Brodell RT. Local reactions to imiquimod in the treatment of basal cell carcinoma. Dermatol Online J 2012;18:1
  10. Stanley MA. Imiquimod and the imidazoquinolones: mechanism of action and therapeutic potential. Clin Exp Dermatol 2002;27:571-7
  11. Tinelli M, Ozolins M, Bath-Hextall F, Williams HC. What determines patient preferences for treating low risk basal cell carcinoma when comparing surgery vs imiquimod? A discrete choice experiment survey from the SINS trial. BMC Dermatol 2012;12:19
  12. Del Rosso JQ. Topical imiquimod therapy for actinic keratosis: is long-term clearance a realistic benefit? J Clin Aesthet Dermatol 2008;1:44-7
  13. Krawtchenko N, Roewert-Huber J, Ulrich M, Mann I, Sterry W, Stockfleth E. A randomised study of topical 5% imiquimod vs. topical 5-fluorouracil vs. cryosurgery in immunocompetent patients with actinic keratoses: a comparison of clinical and histological outcomes including 1-year follow-up. Br J Dermatol 2007;157 Suppl 2:34-40
  14. Stockfleth E, Christophers E, Benninghoff B, Sterry W. Low incidence of new actinic keratoses after topical 5% imiquimod cream treatment: a long-term follow-up study. Arch Dermatol 2004;140